BR112012009423A2 - método de alívio de crescimento de cãncer ou de um simtoma de cãncer, método de sensibilização de ccâncer a fármacos quimioterápicos, método de sensibilização de câncer à radioterapia e pacote de refeição terapêutica para fornecer refeições para um paciente com cãncer que retarda crescimento de cãncer e intensifica a eficácia de fármacos quimioterápicos - Google Patents
método de alívio de crescimento de cãncer ou de um simtoma de cãncer, método de sensibilização de ccâncer a fármacos quimioterápicos, método de sensibilização de câncer à radioterapia e pacote de refeição terapêutica para fornecer refeições para um paciente com cãncer que retarda crescimento de cãncer e intensifica a eficácia de fármacos quimioterápicosInfo
- Publication number
- BR112012009423A2 BR112012009423A2 BR112012009423A BR112012009423A BR112012009423A2 BR 112012009423 A2 BR112012009423 A2 BR 112012009423A2 BR 112012009423 A BR112012009423 A BR 112012009423A BR 112012009423 A BR112012009423 A BR 112012009423A BR 112012009423 A2 BR112012009423 A2 BR 112012009423A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- growth
- sensitization method
- chemotherapy
- intensifies
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q10/00—Administration; Management
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
- A23L13/60—Comminuted or emulsified meat products, e.g. sausages; Reformed meat from comminuted meat product
- A23L13/65—Sausages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
- A23P20/20—Making of laminated, multi-layered, stuffed or hollow foodstuffs, e.g. by wrapping in preformed edible dough sheets or in edible food containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Business, Economics & Management (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Economics (AREA)
- Quality & Reliability (AREA)
- Strategic Management (AREA)
- Tourism & Hospitality (AREA)
- Physics & Mathematics (AREA)
- General Business, Economics & Management (AREA)
- Marketing (AREA)
- Theoretical Computer Science (AREA)
- Human Resources & Organizations (AREA)
- Entrepreneurship & Innovation (AREA)
- Operations Research (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25415409P | 2009-10-22 | 2009-10-22 | |
| PCT/US2010/053821 WO2011050302A2 (en) | 2009-10-22 | 2010-10-22 | Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012009423A2 true BR112012009423A2 (pt) | 2017-06-13 |
Family
ID=43900993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012009423A BR112012009423A2 (pt) | 2009-10-22 | 2010-10-22 | método de alívio de crescimento de cãncer ou de um simtoma de cãncer, método de sensibilização de ccâncer a fármacos quimioterápicos, método de sensibilização de câncer à radioterapia e pacote de refeição terapêutica para fornecer refeições para um paciente com cãncer que retarda crescimento de cãncer e intensifica a eficácia de fármacos quimioterápicos |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20110118528A1 (https=) |
| EP (1) | EP2490684B1 (https=) |
| JP (1) | JP2013508411A (https=) |
| CN (1) | CN102753162A (https=) |
| AU (2) | AU2010310515B2 (https=) |
| BR (1) | BR112012009423A2 (https=) |
| CA (1) | CA2779282C (https=) |
| DK (1) | DK2490684T3 (https=) |
| ES (1) | ES2659353T3 (https=) |
| PL (1) | PL2490684T3 (https=) |
| PT (1) | PT2490684T (https=) |
| RU (1) | RU2549954C2 (https=) |
| WO (1) | WO2011050302A2 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2888811C (en) * | 2012-10-22 | 2023-10-24 | University Of Southern California | A diet package, and uses thereof |
| CN109187991B (zh) | 2013-02-12 | 2021-12-24 | 南加利福尼亚大学 | 为受试者提供合理蛋白质膳食的方法 |
| WO2015002972A1 (en) * | 2013-07-01 | 2015-01-08 | University Of Southern California | Fasting condition as dietary treatment of diabetes |
| US10172839B2 (en) | 2014-03-06 | 2019-01-08 | University Of Southern California | Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues |
| JP6859567B2 (ja) * | 2014-03-06 | 2021-04-14 | ユニヴァーシティ オブ サザン カリフォルニアＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｓｏｕｔｈｅｒｎ Ｃａｌｉｆｏｒｎｉａ | 従来の化学療法剤の効力および実行可能性を増強し、かつ正常な細胞および組織におけるキナーゼの副作用を逆転させるための、キナーゼ阻害剤と併用した短期間絶食レジメンの使用 |
| US10117872B2 (en) * | 2014-03-28 | 2018-11-06 | Università Degli Studi Di Genova | Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake |
| CA2944479C (en) * | 2014-04-02 | 2023-02-21 | University Of Southern California | Dietary formulation and method for treating autoimmune and inflammatory diseases |
| AU2016248443B2 (en) * | 2015-04-16 | 2021-03-18 | University Of Southern California | Fasting mimicking diet (FMD) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone |
| RU2724525C2 (ru) | 2015-05-06 | 2020-06-23 | Юниверсити Оф Саутерн Калифорния | Способ лечения повышенных уровней инсулина или глюкозы с использованием гипокалорийного или бескалорийного рациона или рациона, имитирующего воздержание от пищи |
| EP3352793A1 (en) * | 2015-09-21 | 2018-08-01 | IFOM Fondazione Istituto Firc di Oncologia Molecolare | New therapeutic strategies against blood cancer |
| EP3402345A4 (en) * | 2016-01-12 | 2019-09-11 | University of Southern California | USE OF LONG-TERM FAST FOR IMMEDIATE DIETARY TREATMENT OF MULTIPLE MYELOMA AND OTHER CANCER TYPES |
| JP2019505592A (ja) | 2016-02-15 | 2019-02-28 | ユニバーシティ オブ サザン カリフォルニア | 糖尿病及び他の疾患を治療するための胚様再生を刺激するための薬剤の組み合わせ及び方法 |
| CN109069462A (zh) | 2016-02-23 | 2018-12-21 | 癌症研究科技有限公司 | 缺乏至少两种非必需氨基酸的膳食产品 |
| US11540550B2 (en) | 2016-05-11 | 2023-01-03 | University Of Southern California | Fasting mimicking diet (FMD) as an immunoregulatory treatment for gastrointestinal autoimmune/inflammatory diseases |
| IT201700008499A1 (it) * | 2017-01-26 | 2018-07-26 | Univ Degli Studi Genova | Composizione dietetica per la prevenzione e/o il trattamento dell’iperplasia dell’endometrio |
| US11284640B2 (en) | 2017-02-14 | 2022-03-29 | University Of Southern California | Fasting mimicking diet |
| CN107951892A (zh) * | 2018-01-19 | 2018-04-24 | 丽水学院 | 锌原卟啉在制备增强人结直肠癌细胞对5-氟尿嘧啶化疗敏感性药物中的应用 |
| EP3765046A4 (en) | 2018-03-15 | 2022-04-27 | University Of Southern California | BUT NOT EXCLUSIVELY WATER-BASED DIET (FMD) FACILITATES THE REVERSAL OF INFLAMMATION AND INFLAMMATORY BOWEL DISEASE |
| US20210267250A1 (en) * | 2018-07-18 | 2021-09-02 | Andreas Michalsen | Effects of a short-term fasting mimicking diet on quality of life and tolerance to chemotherapy in patients with cancer |
| MX2021005465A (es) | 2018-11-09 | 2021-12-15 | L Nutra | Barra nutricional para simular el ayuno intermitente. |
| WO2020223522A1 (en) | 2019-04-30 | 2020-11-05 | University Of Southern California | Fasting-mimicking diet (fmd) as an intervention for alzheimer's disease (ad) |
| JP6747702B1 (ja) * | 2019-05-10 | 2020-08-26 | 株式会社医療情報技術研究所 | 栄養処方管理システム |
| WO2020232227A1 (en) | 2019-05-14 | 2020-11-19 | Tyme, Inc. | Compositions and methods for treating cancer |
| IT201900009954A1 (it) * | 2019-06-24 | 2020-12-24 | Fondazione Irccs Istituto Naz Dei Tumori | Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie |
| JP7376718B2 (ja) * | 2019-12-13 | 2023-11-08 | 株式会社ベリタスバイオセラピューティクス | 癌の予防または治療用薬学組成物 |
| IT202000007153A1 (it) | 2020-04-03 | 2021-10-03 | Ifom Fondazione St Firc Di Oncologia Molecolare | Apporto calorico ridotto e immunoterapia per il trattamento del cancro |
| US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
| JP2023530235A (ja) | 2020-06-03 | 2023-07-14 | フェス・セラピューティクス，インコーポレーテッド | 個別化された処置方法のための製剤 |
| WO2021247923A1 (en) | 2020-06-04 | 2021-12-09 | Faeth Therapeutics, Inc. | Personalized methods of treating cancer |
| TW202227113A (zh) | 2020-12-01 | 2022-07-16 | 南加州州立大學 | 模擬禁食飲食提升急性淋巴母細胞白血病模型中的無癌存活 |
| CA3205396A1 (en) * | 2020-12-17 | 2022-06-23 | Licia Rivoltini | Diet preparation for the nutrition of cancer patients with a restricted calorie intake |
| EP4066823B1 (en) | 2021-03-30 | 2025-04-30 | IFOM - Istituto Fondazione di Oncologia Molecolare ETS | Reduced caloric intake and anticancer agents for the treatment of cancer |
| CN115590963A (zh) * | 2022-07-13 | 2023-01-13 | 复旦大学（Cn） | 酮体、酮体诱导剂和生酮组合物中的至少一种在治疗和/或预防血小板减少症药物中的应用 |
| EP4599826A1 (en) | 2024-02-06 | 2025-08-13 | IFOM - Istituto Fondazione di Oncologia Molecolare ETS | Leucine for use in the treatment of cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2074731C1 (ru) * | 1994-12-29 | 1997-03-10 | Игорь Александрович Бойко | Фитокомплекс, обладающий противоопухолевым действием, и способ лечения онкологических больных |
| CA2283642C (en) * | 1997-03-17 | 2012-05-15 | Btg International Limited | Therapeutic compositions |
| AU5319499A (en) * | 1999-07-22 | 2001-02-13 | Ivan L. Cameron | Fatty acids to minimize cancer therapy side effects |
| JP4625156B2 (ja) * | 2000-04-10 | 2011-02-02 | イーエヌ大塚製薬株式会社 | 癌化学療法に伴う副作用軽減剤 |
| WO2005117542A2 (en) * | 2004-05-10 | 2005-12-15 | Novacea, Inc. | Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments |
| WO2006043966A2 (en) * | 2004-10-15 | 2006-04-27 | University Of Tennessee Research Foundation | Methods for inducing apoptosis in adipocytes |
| US20070116802A1 (en) * | 2005-11-23 | 2007-05-24 | Carl Germano | High quality caloric composition |
| US20080038367A1 (en) * | 2006-08-11 | 2008-02-14 | Sal Saloum | Nutritional supplement compositions and methods of preparing |
| RU2354369C2 (ru) * | 2007-03-16 | 2009-05-10 | Михаил Владимирович Кутушов | Применение родамина 6ж в качестве лекарственного средства для лечения злокачественных новообразований и амилоидозов |
| EP2156188B1 (en) * | 2007-03-28 | 2021-05-05 | University of Southern California | Induction of differential stress resistance and uses thereof |
| US20110077198A1 (en) * | 2007-11-26 | 2011-03-31 | Michael John Tisdale | Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition |
-
2010
- 2010-10-22 BR BR112012009423A patent/BR112012009423A2/pt not_active Application Discontinuation
- 2010-10-22 PT PT108257718T patent/PT2490684T/pt unknown
- 2010-10-22 ES ES10825771.8T patent/ES2659353T3/es active Active
- 2010-10-22 CN CN2010800560747A patent/CN102753162A/zh active Pending
- 2010-10-22 CA CA2779282A patent/CA2779282C/en active Active
- 2010-10-22 RU RU2012118588/15A patent/RU2549954C2/ru active
- 2010-10-22 JP JP2012535426A patent/JP2013508411A/ja active Pending
- 2010-10-22 EP EP10825771.8A patent/EP2490684B1/en active Active
- 2010-10-22 DK DK10825771.8T patent/DK2490684T3/en active
- 2010-10-22 WO PCT/US2010/053821 patent/WO2011050302A2/en not_active Ceased
- 2010-10-22 US US12/910,508 patent/US20110118528A1/en not_active Abandoned
- 2010-10-22 AU AU2010310515A patent/AU2010310515B2/en active Active
- 2010-10-22 PL PL10825771T patent/PL2490684T3/pl unknown
-
2016
- 2016-03-11 AU AU2016201607A patent/AU2016201607B2/en active Active
-
2021
- 2021-03-17 US US17/204,419 patent/US20210209516A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT2490684T (pt) | 2018-04-02 |
| DK2490684T3 (en) | 2018-04-09 |
| US20110118528A1 (en) | 2011-05-19 |
| EP2490684B1 (en) | 2018-01-03 |
| US20210209516A1 (en) | 2021-07-08 |
| EP2490684A4 (en) | 2016-05-04 |
| RU2012118588A (ru) | 2013-11-27 |
| JP2013508411A (ja) | 2013-03-07 |
| CA2779282A1 (en) | 2011-04-28 |
| CA2779282C (en) | 2017-12-05 |
| AU2010310515B2 (en) | 2016-01-07 |
| WO2011050302A2 (en) | 2011-04-28 |
| WO2011050302A3 (en) | 2011-08-25 |
| PL2490684T3 (pl) | 2018-07-31 |
| AU2016201607A1 (en) | 2016-03-31 |
| AU2010310515A1 (en) | 2012-05-17 |
| CN102753162A (zh) | 2012-10-24 |
| EP2490684A2 (en) | 2012-08-29 |
| AU2016201607B2 (en) | 2017-11-30 |
| RU2549954C2 (ru) | 2015-05-10 |
| ES2659353T3 (es) | 2018-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012009423A2 (pt) | método de alívio de crescimento de cãncer ou de um simtoma de cãncer, método de sensibilização de ccâncer a fármacos quimioterápicos, método de sensibilização de câncer à radioterapia e pacote de refeição terapêutica para fornecer refeições para um paciente com cãncer que retarda crescimento de cãncer e intensifica a eficácia de fármacos quimioterápicos | |
| BR112013011480A2 (pt) | método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer | |
| AR124500A2 (es) | Aumento de la biodisponibilidad de droga en terapia naltrexona | |
| BR112012018022A2 (pt) | inibição de sinalização axl em terapia antimetastática. | |
| BR112012017150A2 (pt) | formulação de anticorpo e regimes terapêuticos. | |
| BR112016012410A2 (pt) | conjugado de droga e anticorpo, composto conjugado de droga e anticorpo, composto não-peptídico, método de tratamento de doenças em seres humanos e composição farmacêutica | |
| BRPI0813402A2 (pt) | Agente para evitar ou tratar um câncer resistente a trastuzumab, droga combinada, métodos para prevenir ou tratar câncer resistente a trastuzumab, para examinar a sensibilidade de um câncer expressando her2 a um inibidor de her2, para tratar um câncer em um animal julgado ter baixa sensibilidade a um inibidor de her2 e para triar uma droga para a profilaxia ou tratamento de um câncer resistente a trastuzumab, e, uso de um ou mais medicamentos. | |
| BR112012000862A2 (pt) | composição farmaceutica oral, composição farmaceutica oral de baixa dose para administração cronica de tratamento de retardo do inicio ou desenvolvimento de uma condição metodo de tratamento da dor em um individuo que necessita deste medicamento, metodo de tratamento de uma condição em um individuo que necessita deste medicamento | |
| BRPI0813513A2 (pt) | Terapia específica e medicamento usando ligantes de integrina para tratamento de câncer | |
| GT201400059A (es) | Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos | |
| BRPI0821248A2 (pt) | Inibidores de cinesina como fármacos terapêuticos para câncer | |
| ES2425315R1 (es) | Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria | |
| BR112015006656A8 (pt) | composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos | |
| BR112014018450A8 (pt) | Fenilimidazopirazoles substituídos e sua utilização | |
| DeLeve | Cancer chemotherapy | |
| MX2022000394A (es) | Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer. | |
| Theyab et al. | Angiotensin-converting enzyme inhibitor-induced angioedema | |
| Lee et al. | A phase II open label trial of PF-00299804 monotherapy in patients with HER-2 positive advanced gastric cancer after failure of at least one prior chemotherapy regimen | |
| CY1119845T1 (el) | Ενα γαλακτοκομικο προϊον μειωμενης χοληστερολης για χρηση στην θεραπευτικη αντιμετωπιση και/ή προληψη μιας ασθενειας του ηπατος | |
| Fabiny | Ask the doctor. I have just stopped taking a statin drug because it was causing muscle pain. To control my cholesterol I'm now taking ground flaxseed and a daily red yeast rice pill. Are these supplements effective for lowering cholesterol? | |
| Gola | Various toxicities: 12 case reports | |
| Carew et al. | Antagonizing HDAC6 Activity: A New Strategy to Maximize the Anti-Myeloma Effects of BET Inhibition | |
| Celona et al. | 1030–Ocular pigmentation and cataract in therapy with phenothiazine | |
| Park et al. | Clinical Features and Treatment Outcomes of Primary Testicular Lymphoma. | |
| De Both et al. | Compliance with sunitinib treatment in patients with renal cell cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI. |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |